Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The Office of the Inspector General reviewed the FDA’s use of accelerated approval for 24 drugs, ultimately finding issues ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...